Revenue: As of FY2026 Q2, the actual value is USD 7.67 M, missing the estimate of USD 8.35 M.

EPS: As of FY2026 Q2, the actual value is USD -0.05.

EBIT: As of FY2026 Q2, the actual value is USD -4.568 M.

Total Revenue

For the second quarter of 2026, Stereotaxis, Inc. reported total revenue of $7.7 million, a decrease from $8.8 million in the prior year second quarter.

Segment Revenue

System revenue declined to $1.5 million in Q2 2026 from $3.0 million in the previous year, partially offset by initial Synchrony sales. Recurring revenue increased to $6.2 million from $5.8 million in the prior year second quarter, driven by contributions from new robotic catheters. Robotic catheter revenue surpassed $1 million in the quarter, growing 270% sequentially.

Gross Margin

Gross margin for the second quarter of 2026 was 58% of revenue. Recurring revenue gross margin stood at 66%, while system gross margin was 29%.

Operating Expenses

Operating expenses in the second quarter were $9.1 million, which included $2.5 million in non-cash charges. Excluding these non-cash charges, adjusted operating expenses were $6.6 million.

Operating Profit/Loss

Stereotaxis, Inc. recorded an operating loss of - $4.6 million in the second quarter of 2026, compared to an operating loss of - $4.0 million in the previous year. The adjusted operating loss for the quarter was - $2.1 million, compared to - $1.4 million in the prior year.

Net Income/Loss

The company reported a net loss of - $4.5 million in the second quarter of 2026, compared to a net loss of - $3.8 million in the previous year. The adjusted net loss for the quarter was - $2.0 million, compared to - $1.3 million in the prior year.

Cash Flow

Free cash flow for the second quarter was - $3.7 million, consistent with the previous year.

Balance Sheet Highlights

As of June 30, 2026, Stereotaxis, Inc. held $10.5 million in cash and cash equivalents and had no debt.

Operational Achievements

Key operational achievements include the first GenesisX robotic system purchase by a US hospital for installation in Fall 2026 and the sale and installation of multiple Synchrony digital operating room systems following FDA clearance in April. The company also completed the previously announced acquisition of Robocath.

Outlook and Guidance

Stereotaxis, Inc. anticipates recurring revenue to grow to approximately $7 million in the third quarter and $8 million in the fourth quarter of 2026. System revenue is expected to be approximately $3 million in each of the third and fourth quarters. The company expects to reach cash flow profitability in the first half of 2027.